alzheimers-congress-2018-scientifictracks

7 / 10

Page 23
conferenceseries.com
Volume 08 Journal of Alzheimers Disease & Parkinsonism Alzheimer's Congress 2018
May 30-31, 2018
May 30-31, 2018 Osaka, Japan
10th World Congress on
Alzheimer's Disease & Dementia
Novel therapeutic strategies for alzheimer’s disease: Neurotrophy and neurorestoration
Jun Liu
Sun Yat-sen University, China
Alzheimer’sDisease(AD)isaneurodegenerativedisordermainlycharacterizedbyβ-amyloiddeposit,τ-hyperphosphorylation
and neuron loss with no curative treatments. In recent years, the main efforts of multinational pharmaceutical companies
have been focused on reducing the aggregation of Aβ and τ-proteins but with repeated defeats. According to statistics of Adis
R&D, between 1998 and 2014, major pharmaceutical companies launched a total of 123 drugs for AD but only three drugs and
one combination therapy program have been approved by the FDA. However, without exception, none of these 123 drugs can
cure AD and even delay the progression of the disease. So we should shift our focus from alleviating the AD-like pathologies
to neuroprotection, which means the preservation of neuronal structure and/or function. As far as we know, there are some
therapeutic strategies of neuroprotection for AD, such as the application of NMDA receptor antagonists, Acetylcholinesterase
Inhibitors (ACEIs), anti-inflammatory agents, antioxidants, neurotrophins and Chinese medicine and so on. Our research
group has found that neurotropin (a non-protein bioactive agent extracted from rabbit inflamed skins inoculated with Vaccinia
virus vaccine), GQDG (Graphene Quantum Dot Conjugated with neuroprotective peptide-glycine-proline-glutamate),
edaravone, EGb761 (Ginkgo Biloba extract) and β-sitosterol exerted potent neuroprotective effects in AD. In conclusion, a
single cure for AD is unlikely to be found and multi-target therapies should be addressed.
Biography:
Jun Liu has completed his PhD from Sun Yat-sen University and Postdoctoral studies from University of Kansas Medical School. He is currently the Vice Director
of Neurology Department of Sun Yat-sen Memorial Hospital, Sun Yat-sen University. He has been investigating the pathologies and therapeutics of Alzheimer’s
disease and published more than 22 SCI papers as the corresponding author.
Jun Liu, J Alzheimers Dis Parkinsonism 2018, Volume 8
DOI: 10.4172/2161-0460-C4-045